-
EP4083210
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4083210
| EP4083210 - ANTI-CANCER IMMUNOTHERAPEUTIC COMPOSITION FOR TREATING CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 07.07.2021 | Most recent event Tooltip | 07.02.2024 | New entry: Additional fee for renewal fee: despatch of communication + time limit | Applicant(s) | For all designated states Interoligo Corporation (Pyeongchon station Hifield Gwanyang -dong) No.907, F, A-dong, 66 Beolmal-ro, Dongan-gu Anyang-si Gyeonggi-do 14058 / KR | [2022/44] | Inventor(s) | 01 /
LEE, Jung Hwan Yonginseocheon Hyosungherington place, Seocheon- dong) 103-702, 31, Seogeunae-ro, Giheung-gu Yongin-si, Gyeonggi-do 17103 / KR | 02 /
LEE, Jong Ook Sanwoonmaeul 6-danji Apt., Unjung-dong) 607-601 121, Sanun-ro, Bundang-gu Seongnam-si, Gyeonggi-do 13457 / KR | 03 /
KIM, Jin Woo Haneulbaram Humansia, Bongsan dong) 101-1103, 15 Waryong-ro 136beon-gil, Yuseong-gu Daejeon 34006 / KR | [2022/44] | Representative(s) | dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE | [2022/44] | Application number, filing date | 20907917.7 | 07.12.2020 | [2022/44] | WO2020KR17757 | Priority number, date | KR20190176287 | 27.12.2019 Original published format: KR 20190176287 | [2022/44] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021132936 | Date: | 01.07.2021 | Language: | KO | [2021/26] | Type: | A1 Application with search report | No.: | EP4083210 | Date: | 02.11.2022 | Language: | EN | [2022/44] | Search report(s) | International search report - published on: | KR | 01.07.2021 | Classification | IPC: | C12N15/115, A61K48/00, A61K31/713, A61P35/00 | [2022/44] | CPC: |
A61P35/00 (EP,KR,US);
C12N15/115 (EP,KR,US);
A61K31/713 (KR);
A61K48/00 (KR);
A61K49/0054 (US);
A61K51/0491 (US);
C12N2310/16 (EP,KR)
(-)
| C-Set: |
C12N2310/335, C12N2310/3529 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] | Title | German: | ANTI-KREBS-IMMUNTHERAPEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON KREBS | [2022/44] | English: | ANTI-CANCER IMMUNOTHERAPEUTIC COMPOSITION FOR TREATING CANCER | [2022/44] | French: | COMPOSITION IMMUNOTHÉRAPEUTIQUE ANTICANCÉREUSE DESTINÉE À TRAITER UN CANCER | [2022/44] | Entry into regional phase | 24.06.2022 | Translation filed | 24.06.2022 | National basic fee paid | 24.06.2022 | Search fee paid | 24.06.2022 | Designation fee(s) paid | 24.06.2022 | Examination fee paid | Examination procedure | 25.06.2022 | Examination requested [2022/44] | 04.11.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 22.12.2022 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.12.2023 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]KR20130003071 (POSTECH ACAD IND FOUND [KR], et al) [A] 1-14* See entire document. *; | [A]WO2017040620 (ACADEMIA SINICA, et al) [A] 1-14 * See entire document. *; | [A]CN110117595 (SHANDONG ANGKENUO BIOLOGICAL TECH CO LTD) [A] 1-14 * See entire document. *; | [A] - Lai Wei-Yun, Bo-Tsang Huang, Jen-Wei Wang, Pei-Ying Lin, Pan-Chyr Yang, "A novel PD-L1-targeting antagonistic dna aptamer with antitumor effects", Molecular Therapy-Nucleic Acids, (20161213), vol. 5, doi:10.1038/mtna.2016.102, XP055823707 [A] 1-14 * See abstract, pages 1 and 4-5, and figures 1-2. * DOI: http://dx.doi.org/10.1038/mtna.2016.102 | [A] - Yazdian-Robati Rezvan; Ramezani Mohammad; Khedri Mostafa; Ansari Najmeh; Abnous Khalil; Taghdisi Seyed Mohammad, "An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells", MIKROCHIMICA ACTA., SPRINGER VERLAG, VIENNA., AT, AT, (20170802), vol. 184, no. 10, doi:10.1007/s00604-017-2436-4, ISSN 0026-3672, pages 4029 - 4035, XP036318432 [A] 1-14 * See entire document. * DOI: http://dx.doi.org/10.1007/s00604-017-2436-4 | by applicant | - OTT et al., Clin Cancer Res., (20130000), vol. 19, pages 5300 - 5309 | - HAVEL et al., Nat Rev Cancer, (20190000), vol. 19, pages 133 - 150 | - DUNN et al., Nat Rev Chem, (20170000), vol. 1, page 76 | - NG et al., Nat Rev Drug Discovery, (20060000), vol. 5, pages 123 - 132 |